Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

Rosa, C. Aguado de la; Castellanos, Patricia Cruz; Lázaro-Quintela, Martín; Dómine, Manuel; Estévez, Sergio Vázquez; López-Vivanco, G.; Pérez, José Luis Fírvida; Romero, José Luis; Delgado, Lioba Ferrera; Girón, Carlos García; Taín, P. Diz; Álvarez, Rosa; Sanchís, Pilar Mut; Cantón, Inmaculada Fernández; Abós, Isabel Manrique; Aguillo, Maite Martinez; Gutiérrez, Lorenzo Gómez-Aldaraví; Granados, A.L. Ortega; Cabellos, R. Alvarez; Sebastián, Arancha García; Sifuentes, Luis Fernando García; Reguart, Noemı́

doi:10.1016/j.lungcan.2022.09.010

Cited by 6 publications

(2 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In separate studies by Zhang et al (2016); Aguado de la Rosa et al (2022), ALK rearrangements were observed in 5% and 5.5% of patients, respectively. Clinically, ALK rearrangement is associated with younger age, no history of smoking, advanced stage, and occurs more often in females (Fan et al, 2014;Aguado de la Rosa et al, 2022). Interestingly, these aberrations are associated with higher survival in surgically treated lung adenocarcinomas (Matsuura et al, 2023).…”

Section: Anaplastic Lymphoma Kinase-structure and Expressionmentioning

confidence: 99%

Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

Kiełbowski,

Żychowska,

Becht

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Fusions and mutations of anaplastic lymphoma kinase (ALK), a tyrosine kinase receptor, have been identified in several neoplastic diseases. Rearranged ALK is a driver of tumorigenesis, which activates various signaling pathway associated with proliferation and survival. To date, several agents that target and inhibit ALK have been developed. The most studied ALK-positive disease is non-small cell lung cancer, and three generations of ALK tyrosine kinase inhibitors (TKIs) have been approved for the treatment of metastatic disease. Nevertheless, the use of ALK-TKIs is associated with acquired resistance (resistance mutations, bypass signaling), which leads to disease progression and may require a substitution or introduction of other treatment agents. Understanding of the complex nature and network of resistance mutations may allow to introduce sequential and targeted therapies. In this review, we aim to summarize the efficacy and safety profile of ALK inhibitors, describe off-target anticancer effects, and discuss resistance mechanisms in the context of personalized oncology.

show abstract

Section: Anaplastic Lymphoma Kinase-structure and Expressionmentioning

confidence: 99%

Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

Kiełbowski,

Żychowska,

Becht

2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…A study from Spain was the first in the country to examine the effectiveness and safety of crizotinib treatment in ALK-positive patients with advanced NSCLC [ 18 ]. The study was conducted from 2016 to 2019, including patients across 23 hospitals in Spain and a total of 91 patients.…”

Section: Reviewmentioning

confidence: 99%

Adverse Side Effects of Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Mutated Non-small Cell Lung Cancer: A Systematic Review

George,

Shahi,

Ali

et al. 2023

Cureus

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer deaths worldwide, with the majority consisting of non-small cell lung cancer (NSCLC). Genetic mutations present an opportunity for targeted therapy, in addition to current mainstay treatments such as chemotherapy and radiotherapy. Overall, 5% of NSCLCs have an anaplastic lymphoma kinase (ALK) mutation, often prevalent in a younger population. Crizotinib is an ALK inhibitor that was approved to treat ALK-mutated advanced NSCLC. While common side effects such as nausea, fatigue, and diarrhea are mostly well tolerated, adverse side effects can lead to treatment discontinuation or adjustment or can be fatal. This systematic review used articles searched on Google Scholar and PubMed which were assessed using the Cochrane risk-of-bias tool and Newcastle-Ottawa Scale. This yielded nine papers consisting of randomized controlled trials and cohort studies. Side effects resulting in cessation of treatment or dose reduction included liver dysfunction, nausea, neutropenia, and QT prolongation. This review showed that crizotinib has a better side effect profile than chemotherapy in ALK-positive NSCLC, even though toxicities leading to treatment withdrawal are present. Adverse effects were tackled by dose reduction, temporary withdrawal from treatment, and close monitoring.

show abstract

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

Dhamelincourt,

Descourt,

Rousseau-Bussac

et al. 2023

Targ Oncol

View full text Add to dashboard Cite

Identification of ALK-positive patients with advanced NSCLC and real-world clinical experience with crizotinib in Spain (IDEALK study)

Cited by 6 publications

References 47 publications

Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

Anaplastic lymphoma kinase inhibitors—a review of anticancer properties, clinical efficacy, and resistance mechanisms

Adverse Side Effects of Crizotinib in the Treatment of Anaplastic Lymphoma Kinase-Mutated Non-small Cell Lung Cancer: A Systematic Review

Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study)

Contact Info

Product

Resources

About